Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

Syngenta, which has a major operational base in Greensboro, said Wednesday it has signed an agreement to acquire certain product rights from Novartis, along with the recent opening of its ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...